



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Quinine sulfate hydrate

Cat. No.:	HY-W010668
CAS No.:	6119-70-6
Molecular Formula:	C ₂₀ H ₃₀ N ₂ O ₈ S
Molecular Weight:	818.98
Target:	Parasite; Potassium Channel; Flavivirus; Dengue virus
Pathway:	Anti-infection; Membrane Transporter/Ion Channel
Storage:	4°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



BIOLOGICAL ACTIVITY

Description	Quinine sulfate hydrate (2:1:4) is an orally active alkaloid extracted from cinchona bark and can be used in anti-malarial studies. Quinine sulfate hydrate (2:1:4) is a potassium channel inhibitor that inhibits WT mouse Slo3 (K _{Ca} 5.1) channel currents evoked by voltage pulses to +100 mV with an IC ₅₀ of 169 μM ^{[1][2]} .								
In Vitro	<p>Quinine sulfate hydrate (150 μM, 30 min) inhibits the proliferation and cytostatic effects of DENV (Dengue virus) in human hepatocarcinoma HepG2 cell line^[1].</p> <p>Quinine sulfate hydrate (37.5-150 μM, 24 hours) significantly reduces viral DENV RNA and protein levels in a dose-dependent manner in human hepatocarcinoma HepG2 cell line^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human hepatocarcinoma cell line(HepG2)</td> </tr> <tr> <td>Concentration:</td> <td>150 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>30 min</td> </tr> <tr> <td>Result:</td> <td>Inhibited DENV virus replication with 19% yield compared to untreated. Reduced DENV-positive cells from 23.28% to 12.05% in a dose-dependent manner.</td> </tr> </table>	Cell Line:	Human hepatocarcinoma cell line(HepG2)	Concentration:	150 μM	Incubation Time:	30 min	Result:	Inhibited DENV virus replication with 19% yield compared to untreated. Reduced DENV-positive cells from 23.28% to 12.05% in a dose-dependent manner.
Cell Line:	Human hepatocarcinoma cell line(HepG2)								
Concentration:	150 μM								
Incubation Time:	30 min								
Result:	Inhibited DENV virus replication with 19% yield compared to untreated. Reduced DENV-positive cells from 23.28% to 12.05% in a dose-dependent manner.								
In Vivo	<p>Quinine sulfate hydrate (oral gavage, 12 or 15 mg/kg, every week, 16 weeks) has some tumor suppressing effect on skin cancer in Swiss albino mice^[2].</p> <p>Quinine sulfate hydrate (oral gavage, 10 mg/kg, everyday, 8 weeks) causes a decrease in the antioxidant defense system of rat testicular tissue such as SOD, CAT and GSH enzyme activity in male adult albino rats^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Swiss albino mice 7-8-weeks (weighing 24 g)^[2]</td> </tr> <tr> <td>Dosage:</td> <td>12 mg/kg, 15 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; every week; 16 weeks</td> </tr> <tr> <td>Result:</td> <td>Resulted in a significant reduction in tumor size and weight at 12 mg/kg and little effect at</td> </tr> </table>	Animal Model:	Swiss albino mice 7-8-weeks (weighing 24 g) ^[2]	Dosage:	12 mg/kg, 15 mg/kg	Administration:	Oral gavage; every week; 16 weeks	Result:	Resulted in a significant reduction in tumor size and weight at 12 mg/kg and little effect at
Animal Model:	Swiss albino mice 7-8-weeks (weighing 24 g) ^[2]								
Dosage:	12 mg/kg, 15 mg/kg								
Administration:	Oral gavage; every week; 16 weeks								
Result:	Resulted in a significant reduction in tumor size and weight at 12 mg/kg and little effect at								

higher dose of 15 mg/kg.

CUSTOMER VALIDATION

- Mol Med Rep. 2021 Mar 2.
- Norwegian University of Science and Technology, Faculty of Medicine and Health sciences. 2019 Sep.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Shilu Malakar et al. Drug repurposing of quinine as antiviral against dengue virus infection. Virus Res. 2018 Aug 15;255:171-178. doi: 10.1016/j.virusres.2018.07.018. Epub 2018 Jul 25.
- [2]. Jhanwar, Deepika et al. Chemoprevention of DMBA induced skin carcinogenesis in swiss albino mice by quinine sulfate.(2016): 2636-2640.
- [3]. Ebenezer O Farombi, et al. Quercetin protects against testicular toxicity induced by chronic administration of therapeutic dose of quinine sulfate in rats. J Basic Clin Physiol Pharmacol. 2012 Feb 27;23(1):39-44
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA